Machine learning framework for cost effective deep mutational scanning through targeted substitution profiling.

Publication date: May 19, 2026

Deep mutational scanning (DMS) provides comprehensive maps of protein variant effects but remains experimentally intensive. Machine learning (ML) approaches have the potential to reduce experimental burden of DMS by predicting the functional impact of substitutions from limited data. We introduced a ML classifier trained on normalised DMS scores from SARS-CoV-2 main protease (Mpro) to categorise amino acid substitutions as functional (wild-type-like) or non-functional. Using brute-force feature selection, we identified minimal subsets of six substitution scores per residue that enable accurate classification of the remaining substitutions, achieving minimum (worst accuracy) scores exceeding 90%. Models including support vector machines, random forests, and logistic regression were evaluated without retraining (zero-shot prediction) against additional SARS-CoV-2 Mpro datasets and against unrelated datasets. The zero-shot performance of the models was strongest for other enzymes and more modest when applied to DMS systems that assess protein folding and/or protein-protein interactions. The results show that targeted DMS combined with ML can reduce sequencing and reagent costs while preserving classification accuracy, offering a practical route to accelerate variant effect prediction.

Open Access PDF

Concepts Keywords
Accurate Brute-force approach
Enzymes Deep mutational scanning
Forests Random Forest
Retraining Support vector machine
Unrelated Zero-shot prediction

Semantics

Type Source Name
drug DRUGBANK Succimer
pathway REACTOME Protein folding
pathway REACTOME Reproduction
disease MESH included
disease MESH cam
drug DRUGBANK L-Alanine
drug DRUGBANK Tropicamide
disease MESH DMSD
drug DRUGBANK Amino acids
drug DRUGBANK Aspartame
drug DRUGBANK Papain
drug DRUGBANK Tretamine
drug DRUGBANK Ampicillin
drug DRUGBANK Methyldopa
drug DRUGBANK Glycine
drug DRUGBANK Proline
drug DRUGBANK Indole
drug DRUGBANK L-Asparagine
drug DRUGBANK Histidine
drug DRUGBANK L-Glutamine
drug DRUGBANK L-Threonine
drug DRUGBANK L-Tyrosine
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Glutamic Acid
drug DRUGBANK L-Isoleucine
drug DRUGBANK L-Leucine
drug DRUGBANK Methionine
drug DRUGBANK L-Phenylalanine
drug DRUGBANK L-Valine
drug DRUGBANK L-Cysteine
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Nitrogen
drug DRUGBANK Activated charcoal
drug DRUGBANK Coenzyme M
disease MESH Bed
disease MESH Dis
drug DRUGBANK Guanosine
disease MESH Breast Cancer
pathway KEGG Breast cancer

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *